Fizy health
Refill volume pricing

How does volume affect Refill pricing?

Refill's volume pricing model pools clinic demand across its 503A pharmacy network to negotiate aggregate pre-negotiated medication rates, then passes those rates to individual accounts. Refill advertises a meet-or-beat or price-match guarantee against competing quotes. Software fees on transactions, published at roughly 1.5–5% depending on platform tier, scale with order volume independently of the medication rate. Because Refill does not publish per-vial tiers on its public site, how volume moves your medication rate is confirmed at demo rather than on a published curve.

This page explains Refill's aggregate leverage model, where software fees fit in, and how to compare volume economics against pass-through pricing you can read before checkout.

Compare Fizy Health vs Refill
Aggregate network leverage Meet-or-beat guarantee Volume and software fees Pre-negotiated 503A rates Pass-through alternative Landed cost comparison

What Refill's volume pricing model is

Refill volume pricing is aggregate, not a published tier table. The platform negotiates medication cost across pooled clinic demand with its 503A partner network, then offers pre-negotiated rates to individual clinics. Refill advertises that aggregate leverage can beat solo pharmacy contracts and backs it with a meet-or-beat guarantee against competing quotes. Transaction software fees, roughly 1.5–5% per published platform tiers, apply on every order and grow with volume spend even when the medication rate improves. Understanding both layers is essential: a better aggregate drug rate paired with a higher software fee percentage can cost more at scale than pass-through pricing with a disclosed flat facilitation fee.

Where aggregate leverage helps and where fees claw it back

Aggregate pricing can genuinely lower medication cost when Refill's network volume earns better 503A rates than a clinic negotiating alone. The meet-or-beat guarantee is Refill's public commitment that competing quotes can be matched on medication pricing. The clawback is the software fee layer: as order volume grows, total software fee dollars grow with it because the fee is percentage-based on transactions within published tiers. A clinic ordering hundreds of GLP-1 refills monthly pays more in software fees than a low-volume account on the same tier, even if the per-vial medication rate is attractive.

The harder issue with any unpublished volume model is verification. Without public per-vial tiers, you cannot independently check whether the rate you receive reflects the volume you bring. Get the medication rate curve and software fee tier in writing for your top SKUs, and model total cost at your actual monthly order count, not a headline savings claim.

Comparing volume economics at your real order count

Fizy Health does not use aggregate negotiation or percentage software fees. Resolved per-vial 503A cost shows on each catalog and cart line before checkout, with a disclosed facilitation fee at payment. For volume comparison, build a representative month: multiply Refill's confirmed per-vial medication rate plus software fee percentage across your actual order count, add platform subscription and shipping, and set that total against visible pass-through cost plus facilitation fee on the same SKUs.

Refill wins when aggregate medication leverage plus meet-or-beat terms beats pass-through on your top lines after all fees. Fizy Health wins when your team prescribes in-house, needs landed cost before the consult, and wants batch refill-day checkout without a growing percentage fee on every transaction.

Buy aggregate leverage — or buy visible landed cost at volume?

Refill fits if

Refill

Network volume earns rates that justify software fees at your scale.

  • Pre-negotiated aggregate pricing beats your solo contracts after software fees at your monthly order count.
  • Meet-or-beat terms cover your top SKUs and you can verify them in writing at demo.
  • You need bundled telehealth infrastructure and accept percentage fees that scale with volume.
Consider Fizy Health if

Fizy Health

You prescribe in-house and compare landed cost at real volume today.

  • You want per-vial 503A cost visible before checkout without modeling unpublished volume tiers.
  • You want to avoid percentage software fees that grow with every GLP-1 refill you process.
  • You batch high-volume refill days and need one cart with per-line cost before one payment.
If you choose Fizy Health

What high-volume clinics get when cost scales predictably.

Refill volume economics depend on demo-confirmed rates plus software fees. These outcomes show cost at your real order count.

See all features
Keep evaluating Refill pricing

More on Refill volume economics.

See the full Refill pricing guide
FAQ

What clinics ask about Refill volume pricing.

  • Model

    How does Refill volume pricing work?

    Refill pools clinic demand to negotiate aggregate pre-negotiated 503A medication rates across its partner network, then passes those rates to individual accounts. Transaction software fees, roughly 1.5–5% per published tiers, apply on every order and scale with spend.

  • Guarantee

    What is Refill's meet-or-beat guarantee?

    Refill advertises a price-match or meet-or-beat guarantee on aggregate medication pricing. Confirm at demo which SKUs qualify, what competitor documentation is required, and how long matched rates hold across refill cycles.

  • Fees

    Do software fees grow with volume on Refill?

    Yes. Published tiers charge a percentage software fee on transactions, so total software fee dollars increase as order volume and spend grow, even when the per-vial medication rate improves through aggregate leverage.

  • Verification

    Can I verify Refill volume tiers independently?

    Refill does not publish per-vial volume tiers on its public site. Get medication rates and software fee tier in writing at demo and model total cost at your actual monthly order count.

  • Comparison

    How does Fizy Health handle volume pricing?

    Fizy Health shows resolved per-vial 503A cost before checkout with a disclosed facilitation fee, without percentage software fees on transactions. Volume comparison is total landed cost at your order count, not unpublished tier curves.

  • GLP-1

    Does Refill volume pricing favor GLP-1-heavy clinics?

    Aggregate leverage can help on high-volume SKUs, but percentage software fees compound on GLP-1 refill counts. Model all-in cost at your actual semaglutide and tirzepatide volume before assuming aggregate pricing wins.

Sources reviewed June 2026

  • Refill public website and published pricing tiers in Refill web app (refill.co), reviewed June 2026.
  • Fizy Health platform capabilities reflect the live product.
Evaluate with real numbers

Compare volume economics on numbers you can read.

Model landed cost at your real refill count, batch one checkout, and decide whether aggregate leverage or pass-through wins. Free to start.

Start Ordering Free Fizy Health vs Refill